The fibrosis marker galectin-3 and outcome in the general population. - Wikidata - awgldk - TriplyDB

The fibrosis marker galectin-3 and outcome in the general population.

The fibrosis marker galectin-3 and outcome in the general population.

http://www.wikidata.org/entity/Q48821773

about

Vascular Fibrosis in Aging and Hypertension: Molecular Mechanisms and Clinical Implications The Role of Galectin-3 in the Kidneys Role of Galectin-3 in Obesity and Impaired Glucose Homeostasis State of the Art: Newer biomarkers in heart failure Epidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches.Galectin 3 and incident atrial fibrillation in the community.Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study Clinical Correlates and Prognostic Value of Plasma Galectin-3 Levels in Degenerative Aortic Stenosis: A Single-Center Prospective Study of Patients Referred for Invasive Treatment Dysregulation of galectin-3. Implications for Hermansky-Pudlak syndrome pulmonary fibrosis.Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure.A genome-wide association study of circulating galectin-3 Increased adiposity, dysregulated glucose metabolism and systemic inflammation in Galectin-3 KO mice.Cord blood neutrophils display a galectin-3 responsive phenotype accentuated by vaginal delivery.Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis.Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis.The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand?Serum galectin-3 levels in children with chronic hepatitis B infection and inactive hepatitis B carriers Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation.Plasma galectin 3 and heart failure risk in the Physicians' Health Study.Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.Serum Galectin and Renal Dysfunction in ST-Segment Elevation Myocardial Infarction.Circulating Galectin-3 Is Associated With Cardiometabolic Disease in the Community.Galectin 3 complements BNP in risk stratification in acute heart failure.Galectin-3 and Risk of Heart Failure and Death in Blacks and Whites.Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling Elevated galectin-3 precedes the development of CKD Serial galectin-3 and future cardiovascular disease in the general population.Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke.Galectin-3 in heart failure with preserved ejection fraction.Advanced glycation end-products: a common pathway in diabetes and age-related erectile dysfunction.Does cirrhotic cardiomyopathy exist? 50 years of uncertainty.The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers.Significance of sugar chain recognition by galectins and its involvement in disease-associated glycosylation.The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure.Galectin-3: a modifiable risk factor in heart failure.Markers of left ventricular decompensation in aortic stenosis.Biomarkers for risk prediction in acute decompensated heart failure.

P2860

Q26749488-CEA2FFED-9673-4B08-B5B7-1E49D90F4151 Q26752754-2F2F52F6-B33E-43F6-8B89-C5D5AAC7E9EB Q26771826-33D2D1AF-08AA-45C5-99C6-BCD0E74A98FB Q27027899-A7C24B94-7C0D-48B1-803D-19A0D09C5CDD Q30251632-667B3146-CEF6-4AD4-B4C7-92EFC1E729AF Q33555143-F4318C92-2EA6-408A-8A5E-ADD0D6C51FF7 Q33577541-38B5B886-A38B-46F7-8389-88C9A9A49FE4 Q33754895-14C2E0E4-AD9D-4811-94D0-1FADE73BCCBA Q33799623-4165B09A-B967-4260-8762-26C879D354D6 Q34102031-0C6917E7-7FEC-4FB5-B05C-284188536B04 Q34443077-4A79EBBC-3ED7-4EE8-A094-D1278756973F Q34603941-BEECFD9F-482A-4AC7-AF8D-0ECD4ADD84BA Q34960351-80194BE6-2EA0-4690-9297-11F2C215093C Q35026202-CB20C30C-F33A-4F13-92A2-FECC7E28F694 Q35070734-8A606E48-985B-48B0-A442-BD27709565BA Q35191679-F45C6562-4DBD-47FF-BB59-B64D70CED50C Q35206146-8E54EC06-73CF-4A69-A118-BFEDC0A14970 Q35286926-EE1366C8-BBF2-4379-990F-5329FF897500 Q35994160-16B9DF56-D5C7-4B7A-B3E2-075B932D2D16 Q36003071-FC0750A4-380F-4102-A14A-CDE7098105F2 Q36052222-EAF331C9-B9B7-4ED5-A904-96EB0CF02183 Q36283028-D756B435-8E8C-4793-98D3-942CF065A12F Q36439679-30848F45-229A-44E6-BAE3-AF5F6758A4BF Q36627699-0D94F58A-0020-483D-B1B5-740FEEBEA5A4 Q36877555-52FFB252-819E-4593-AE64-F96F0174D198 Q36917873-685B9C60-2999-4A01-AB08-E7F621F9998A Q36956715-F5A60D6E-B2F9-47A6-818F-2C5DE09700A2 Q37096257-5571B354-6F2E-4792-96BB-B587356291A3 Q37119904-82B8533C-70A8-47EB-BCD4-39C903F3A7A8 Q37580709-6667055D-31A8-43A0-98AD-789E568B3706 Q37599836-C0F676CA-0D47-49D1-9E9F-31290AC9B8B6 Q38104695-F98E9682-4711-4D7F-BDA2-6C5619C7C06E Q38118993-FCA10A04-54D0-4E4C-B9FB-607ED7571B71 Q38133308-22817003-6259-480E-806A-4222A2387BC6 Q38154222-331287C2-4897-43EE-9276-8D7A311E1FFA Q38180714-AF56B057-C1FF-42E8-8479-326C37766775 Q38194209-B7B43473-861B-4759-8C53-60DAF777D895 Q38208784-4A919185-F5ED-42C9-8DAE-842DEDB4DAB7 Q38215381-3D33CCA1-D538-4314-8EE5-CDAF868ADF0B Q38222370-97FCF478-B20C-4125-9423-647B0E6C7BF5

P2860

The fibrosis marker galectin-3 and outcome in the general population.

http://www.wikidata.org/entity/Q48821773

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

The fibrosis marker galectin-3 and outcome in the general population.

@en

The fibrosis marker galectin-3 and outcome in the general population.

@nl

type

label

The fibrosis marker galectin-3 and outcome in the general population.

@en

The fibrosis marker galectin-3 and outcome in the general population.

@nl

prefLabel

The fibrosis marker galectin-3 and outcome in the general population.

@en

The fibrosis marker galectin-3 and outcome in the general population.

@nl

P1433

Q48821773-7233802A-025D-4F7C-8619-4170951B1C10

P1476

Q48821773-B2A2BCFB-AAD1-4128-9DE6-0F5D579A2EDA

P2093

Q48821773-12ED13B3-B56B-4943-BA4E-498E7DE7A5D4

Q48821773-63782CA2-4123-4E1A-9303-330D03023313

Q48821773-6FB3289F-FF40-4D0E-9B7B-09A2C086A8F2

Q48821773-7950F8EF-82C2-4579-94C4-6B505D01ACA9

Q48821773-9773A579-F74C-4D20-8E01-2DD56724D92D

Q48821773-D033AACB-2551-4A89-AC98-CC223563F4C0

Q48821773-EBA800B5-2F9E-4FC5-849C-65E849035E02

P2860

Q48821773-037E674D-2279-4208-915C-AA2A105800FF

Q48821773-0E79937A-7EDB-4EC2-B4EA-478ADE0B7BFD

Q48821773-1185454E-D786-4090-ABA6-82088EE7E0D1

Q48821773-20C33B69-6475-46F3-AEC1-2FE466530D32

Q48821773-25189065-A953-42AC-8D85-8937C4EA5830

Q48821773-29943A81-17CF-45C6-A3AB-5A9A1D23034D

Q48821773-2DA22A1E-B924-4199-8DD1-DCED2E37417A

Q48821773-48810178-606F-4423-A7C8-A387896605B9

Q48821773-53E89455-F84E-435F-B7F0-99FA2E41ACD2

Q48821773-5B70AA25-E31F-4986-B85A-9EF6DADDB11F

P304

Q48821773-503BE7E4-3211-41B1-853D-3C255ECBB271

P31

Q48821773-F254825A-1FE5-4167-9C46-BFA24855C75D

P356

Q48821773-CE88F591-ADC6-49E5-9908-5DCA55C0D706

P407

Q48821773-1A3D3325-68BD-4C4B-A9A7-CCDFF636C616

P433

Q48821773-F079CE2B-E162-4FE3-9A83-628007D8AEB4

P478

Q48821773-74BFDFCB-07C4-4963-9BD6-B732B9387A95

P50

Q48821773-6CEC341B-A3E3-480F-BE2D-F9BC5366EB22

P577

Q48821773-13CDF54B-E9D9-46AE-A680-AE31BCE09B7C

P5875

Q48821773-A0D15F3F-2081-4DD0-B6C3-D88713504D37

P698

Q48821773-D32738FB-0DA4-4D5E-AB64-820E5D6A18BE

P356

J.1365-2796.2011.02476.X

P1433

Journal of Internal Medicine

P1476

The fibrosis marker galectin-3 and outcome in the general population.

@en

P2093

A C Muller Kobold

http://www.w3.org/2001/XMLSchema#string

D J van Veldhuisen

http://www.w3.org/2001/XMLSchema#string

H L Hillege

http://www.w3.org/2001/XMLSchema#string

P van der Harst

http://www.w3.org/2001/XMLSchema#string

R A de Boer

http://www.w3.org/2001/XMLSchema#string

R T Gansevoort

http://www.w3.org/2001/XMLSchema#string

S J L Bakker

http://www.w3.org/2001/XMLSchema#string

P2860

Galectin-3 regulates myofibroblast activation and hepatic fibrosis

Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis

N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin

Galectins: structure, function and therapeutic potential

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Nuclear localization of Galectin-3 in transformed thyroid cells: a role in transcriptional regulation.

Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.

The extracellular matrix: at the center of it all.

Diagnostic utility of galectin-3 in thyroid cancer.

Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy.

P304

55-64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2796.2011.02476.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

272

http://www.w3.org/2001/XMLSchema#string

P50

Wiek H van Gilst

P577

2011-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51744632

http://www.w3.org/2001/XMLSchema#string

P698

22026577

http://www.w3.org/2001/XMLSchema#string